Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables (2016 - 2025)

Historic Receivables for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $181.5 million.

  • Ascendis Pharma A's Receivables fell 330.63% to $181.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $181.5 million, marking a year-over-year decrease of 330.63%. This contributed to the annual value of $176.2 million for FY2025, which is 613.43% down from last year.
  • As of Q4 2025, Ascendis Pharma A's Receivables stood at $181.5 million, which was down 330.63% from $157.5 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Receivables high stood at $187.7 million for Q4 2024, and its period low was $72374.2 during Q1 2021.
  • For the 5-year period, Ascendis Pharma A's Receivables averaged around $52.7 million, with its median value being $27.3 million (2021).
  • Per our database at Business Quant, Ascendis Pharma A's Receivables plummeted by 8023.09% in 2021 and then surged by 890671.85% in 2022.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Receivables stood at $25.5 million in 2021, then dropped by 1.01% to $25.2 million in 2022, then surged by 134.3% to $59.1 million in 2023, then soared by 217.38% to $187.7 million in 2024, then fell by 3.31% to $181.5 million in 2025.
  • Its last three reported values are $181.5 million in Q4 2025, $157.5 million for Q3 2025, and $125.0 million during Q2 2025.